Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. Department of War committed $450 million to The Elmet Group to secure domestic tungsten production.
  • Elmet will expand manufacturing capacity in Maine, Michigan, and Ohio.
  • Elmet will restart mining operations at the Springer Tungsten Complex.
  • Elmet will modernize processing through a joint venture at Springer.
  • Elmet is launching an Elmet Refining & Trading division to coordinate its global tungsten supply network.
  • Elmet secured up to a $2 billion Defense Logistics Agency contract to supply tungsten to the National Defense Stockpile.
  • The move supports U.S. defense, aerospace, and advanced industrial suppliers.

Latest Articles

Aebi Schmidt Group Reports 22% Increase in Adjusted EBITDA, 16% Growth in Order Intake and 9% Increase in Net Sales, Reflecting Strong Order Momentum and Over-Proportional Profitability Improvement
Aug 13, 2026
Priya Menon
Press Releases

Aebi Schmidt Group Reports 22% Increase in Adjusted EBITDA, 16% Growth in Order Intake and 9% Increase in Net Sales, Reflecting Strong Order Momentum and Over-Proportional Profitability Improvement

Aebi Schmidt Group reported a 22% increase in adjusted EBITDA and a 16% growth in order intake for Q2 2026 compared to Q2 2025, alongside a 9% rise in net sales. The company attributes its improved profitability to operational improvements and an expanded market footprint, with strong performance in North America and Europe. Net income turned posit…

AEBI
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
Aug 13, 2026
Jordan Park
Press Releases

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

Nutriband Inc.'s CEO Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit focusing on the company's AVERSA™ abuse-deterrent transdermal technology designed to prevent abuse and accidental exposure of drugs like fentanyl. The technology is covered by broad international patents and aims to improve safety profiles of transdermal drug…

NTRB
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Aug 13, 2026
Nina Shah
Press Releases

Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on breast cancer therapies, announced the appointment of Jason O’Byrne as Chief Financial Officer. With a strong background in biotech finance and operations, O’Byrne will support Olema as it approaches key clinical data readouts and prepares for its initial commercial launch…

OLMA
FactSet Declares Dividend
Aug 13, 2026
Caleb Monroe
Press Releases

FactSet Declares Dividend

FactSet has announced a quarterly cash dividend of $1.16 per share, payable on September 17, 2026, to shareholders of record as of August 31, 2026. The company continues to demonstrate commitment to delivering value to shareholders amid its ongoing provision of financial intelligence and AI solutions globally.

FDS
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Aug 13, 2026
Avery Klein
Press Releases

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology reported its Q2 2026 financial results and highlighted progress in its MICVO clinical programs targeting recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The company completed a private placement raising approximately $50 million upfront, extending its cash runway into Q2 2027. Updated data from Phase 1 monothe…

PYXS
Rocket Lab Corporation Announces Progress on Iridium Acquisition: HSR Period Lapses; Form S-4 Filed; FCC Applications Filed; Capital Strategy Underway
Aug 13, 2026
Avery Klein
Press Releases

Rocket Lab Corporation Announces Progress on Iridium Acquisition: HSR Period Lapses; Form S-4 Filed; FCC Applications Filed; Capital Strategy Underway

Rocket Lab Corporation has reached important milestones in its planned acquisition of Iridium Communications, including the lapse of the Hart-Scott-Rodino antitrust waiting period, filing a Form S-4 registration statement with the SEC, and submitting FCC applications to transfer control of Iridium's licenses. The company is advancing its capital st…

RKLB
Xanadu and University of Alberta Partner to Accelerate Pharmaceutical Discoveries with Quantum Computing
Aug 13, 2026
Nina Shah
Press Releases

Xanadu and University of Alberta Partner to Accelerate Pharmaceutical Discoveries with Quantum Computing

Xanadu Quantum Technologies has entered a strategic research partnership with the University of Alberta to develop quantum computing algorithms aimed at accelerating discovery of next-generation photosensitizers for photodynamic cancer therapy. This collaboration seeks to leverage quantum computing to overcome current limitations in drug discovery …

XNDU
SOLV Energy Reports Second Quarter 2026 Financial Results
Aug 13, 2026
Hana Yamamoto
Press Releases

SOLV Energy Reports Second Quarter 2026 Financial Results

SOLV Energy, Inc. reported record second quarter 2026 financial results highlighted by a 77% year-over-year revenue increase to $951 million and strong adjusted EBITDA of $117 million. The company closed the acquisition of Roberson Waite Electric, expanding its capabilities in utility substation construction. With a backlog up 44% year-over-year to…

MWH
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Aug 13, 2026
Avery Klein
Press Releases

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

Beyond Air, Inc. announced its Q2 2026 financial results with revenue of $1.8 million and a net loss of $7.9 million. The company reaffirmed its revenue guidance of $8 million for 2026 and $16-$18 million for 2027, anticipating more than 110% growth with the launch of its second-generation LungFit PH system pending FDA approval. The company recentl…

XAIR
Profusa Announces 1-for-4 Reverse Stock Split
Aug 13, 2026
Derek Hwang
Press Releases

Profusa Announces 1-for-4 Reverse Stock Split

Profusa, Inc., a digital health company trading on Nasdaq under PFSA, announced a one-for-four reverse stock split effective August 17, 2026, consolidating every four shares into one to reduce outstanding shares and maintain compliance with Nasdaq listing requirements. The company's authorized shares remain unchanged, and fractional shares will be …

PFSA
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
Aug 13, 2026
Hana Yamamoto
Press Releases

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

Sagimet Biosciences received FDA clearance and a 'Study May Proceed' letter for its Phase 3 clinical trial of denifanstat, an oral FASN inhibitor targeting moderate to severe acne. The multi-center, randomized, double-blind trial will enroll approximately 800 U.S. patients, including adolescents, with dosing expected to start in the second half of …

SGMT
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Aug 13, 2026
Avery Klein
Press Releases

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion announced dosing the first participant in a new arm of the OPAL adaptive platform trial that evaluates icovamenib in combination with low-dose semaglutide in overweight or obese individuals without type 2 diabetes. The study aims to assess if adding icovamenib to semaglutide improves weight loss, physical function, body composition, m…

BMEA
Markets Find Temporary Respite as Inflation Data Lacks a Shock
Aug 13, 2026
Derek Hwang
Commodities

Markets Find Temporary Respite as Inflation Data Lacks a Shock

July's consumer price readings provided modest relief to markets concerned about an upside inflation surprise. Annual headline and core inflation eased as expected, though the monthly core reading was slightly firmer than forecasts. Markets pared the probability of a Federal Reserve rate increase next month to just under 50%, but attention now shif…